stockrow
Saturday 7 November 2026
Export AMRX’s income statement to Excel — free account
AMNEAL PHARMACEUTICALS, INC.
AMRX Healthcare Drug Manufacturers Specialty & Generic
AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.
- Revenue
- +9.96%
- EPS
- +267.0%
- Free cash flow
- −50.9%
- Total debt
- +23.8%
Quarter to September 2026, against a year earlier
20.11
0.66
+3.39%
Follow AMRX
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
38.24 | 34.62 | 31.87 | 54.78 |
+8 more quarters Free account |
P/S ratio |
2.12 | 1.77 | 1.29 | 1.31 | |
P/FCF ratio |
0.00 | 0.00 | 20.71 | 17.34 | |
P/Operating CF |
68.79 | (260.09) | (146.89) | 30.30 | |
P/B ratio |
61.78 | 167.31 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
3.06 | 2.59 | 2.09 | 2.06 | |
EV/EBITDA |
14.70 | 12.12 | 9.60 | 9.70 | |
EV/Operating CF |
54.12 | 40.14 | 20.77 | 18.26 | |
EV/FCF |
(161.67) | (695.25) | 33.50 | 27.27 | |
Quick Ratio |
1.06 | 1.31 | 1.45 | 1.37 | |
Current Ratio |
1.87 | 2.20 | 2.47 | 2.17 | |
Net Debt/EBITDA |
0.00 | 13.95 | 12.84 | 13.71 | |
Debt/Assets |
60.47% | 70.71% | 74.19% | 69.92% | |
Debt/Equity |
6.00 | 80.86 | (57.14) | (36.06) | |
Asset Turnover |
0.72 | 0.87 | 0.88 | 0.84 | |
Operating CF/Net income |
(4.53) | (0.37) | (0.43) | 3.72 | |
Capex/Depreciation |
(0.89) | (2.37) | (0.46) | (0.86) | |
Interest Coverage |
1.62 | 2.36 | 2.66 | 1.99 | |
Research and Development Expense of Revenue |
7.93% | 4.90% | 5.31% | 4.28% | |
Selling, General and Administrative Expense of Revenue |
16.19% | 18.68% | 19.22% | 17.99% | |
Intangible Assets out of Total Assets |
0.44 | 0.31 | 0.32 | 0.32 | |
Share Based Compensation of Revenue |
1.22% | 1.31% | 1.22% | 1.01% | |
Graham Net Nets |
(0.37) | (0.33) | (0.46) | (0.47) | |
Graham Number |
1.97 | 1.08 | 0.00 | 0.00 | |
Earnings Yield |
2.62% | 2.89% | 3.14% | 1.83% | |
Free Cash Flow Yield |
(0.89%) | (0.21%) | 4.83% | 5.77% | |
Revenue per Share |
2.57 | 2.49 | 2.29 | 2.60 | |
Operating CF per Share |
0.29 | (0.07) | (0.08) | 0.42 | |
Capex per Share |
(0.15) | (0.38) | (0.07) | (0.15) | |
Free Cash Flow per Share |
0.14 | (0.45) | (0.15) | 0.27 | |
Cash per Share |
0.51 | 0.43 | 0.64 | 0.99 | |
Shareholders Equity per Share |
1.58 | 0.10 | (0.15) | (0.23) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.58 | 0.10 | (0.15) | (0.23) | |
Free Cash Flow |
47.11 | (143.99) | (48.45) | 84.86 | |
Working Capital |
975.18 | 1,063.84 | 1,069.86 | 1,029.55 | |
Capital Expenditures |
(51.19) | (122.74) | (21.71) | (45.45) | |
Net Current Asset Value |
(2,531.49) | (1,796.29) | (1,788.28) | (1,838.43) | |
EV/EBIT |
20.41 | 17.76 | 14.59 | 15.76 | |
Capex to Sales |
0.06 | 0.15 | 0.03 | 0.06 | |
Price to Operating Income |
14.12 | 12.17 | 9.02 | 10.02 | |
| Other line items | |||||
Average Receivables |
952.61 | 915.01 | 803.05 | 835.91 | |
Average Payables |
760.33 | 694.01 | 645.77 | 748.38 | |
Average Inventory |
661.23 | 643.46 | 621.53 | 609.38 | |
Average Assets |
4,433.55 | 3,599.57 | 3,452.73 | 3,589.86 | |
Average Common Equity |
(0.25) | (39.75) | (88.98) | (90.42) |
Columns are period end dates · fundamentals updated 5 Nov 2026